“PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials”, Biomed. Res. Ther., vol. 10, no. 12, pp. 6090–6102, Dec. 2023, doi: 10.15419/bmrat.v10i12.851.